Interchangeability of biological drugs: Considerations about the approval of biogeneric formulations in Chile;Intercambiabilidad de medicamentos de origen biológico (biofármacos): Consideraciones acerca de la aprobación de formulaciones biosimilares (biogenéricos) en Chile

Revista Medica de Chile

Volumn 134, Issue 12, 2006, Pages 1583-1588

  Saavedra Saavedra, Iván ^a   Quiñones S, Luis ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Drug industry; Erythropoietin; Heparin, low molecular weight; Human growth hormone

Indexed keywords

BIOLOGICAL PRODUCT;

CHILE; HUMAN; POSTMARKETING SURVEILLANCE; REVIEW;

BIOLOGICAL PRODUCTS; CHILE; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 33846552526     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Tratado de Cooperacion en Materia de Patentes (PCT) (19/06/1970), elaborado en Washington, enmendado el 02/10/1979 y modificado el 03/02/1984, y su reglamento (BOE 26/11/1986).
2. MINSAL. Reglamento del sistema nacional de registro de productos farmacéuticos. Decreto Supremo 1876, 1995.
3. OMS. Guideline. Multisource (generic) pharmaceutical products: guidelines on registration requirements to stablish interchangeability. WHO Technical Reports Series 863: 114-55.
4. FDA. Drug Price Competition and Patent Term Restoration Act of 1984, Publ. L. No98-417, 98 Stat. 1585.
5. Fareed J, Leong W, Hoppesteadt DA. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 2004; 30(6): 703-13.
6. Committee for the Propietary Medicinal Products. Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance. Quality issues. Evaluation of medicine for human use. The European Agency for the Evaluation of Medicinal Products, London; 2003.
7. Schellekens H. Follow-on biologics: challenges of the «next generation». Nephrol Dial Transplant 2005; 20(4): iv31-iv36.
8. Chirino AJ, Mire-Sluis A. Characterizating biological products and assessing comparability following manufacturing changes. Nature Biotechnol 2004; 22: 1383-91.
9. European Parliament and Council. Regulation (EC) No 726/2004 of the European Parliament. Europa L136 2004; 47.
10. Committee for the Propietary Medicinal Products. Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance. Non-clinical and clinical issues. Evaluation of medicine for human use. The European Agency for the Evaluation of Medicinal Products, London; 2003.
11. Schellekens H. Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia. Curr Med Res Opin 2003; 19: 433-4.
12. Haselbeck A. Epoetins: differences and their relevance to immunogenicity. Curr Med Res Opin 2003; 19: 430-2.
13. Nightingale SL. From the food and drug administration. JAMA 1993; 270: 1672.
14. Hirsh J, Warkentin TE, Raschke R. Heparin and low molecular weight heparin: mechanism of action, pahramcokinetics, dosing considerations, monitoring, afficacy and safety. Chest 1998; 114(5): 489s-510s.
15. Fareed J, Fu K, Yang LH. Pharmacokinetics of low molecular weight heparins in animal models. Semin Thromb Hemost 1999; 25(3): 51-5.
16. Storring PL, Tiplady RJ, Gaines Das Re et al. Epoetin alfa and beta differ in their eritropietin isoform compositions and biological properties. Br J Haematol 1998; 100: 79-89.
17. Raines LJ. Bad medicine: why the generic drug regulatory paradigm is inapplicable to biotechnology products. Biolaw bus 2002; 5: 6-13.
18. Schellekens H. Biosimilar epoetins: how similar are they. Eur J Hosp Pharm 2004; 3: 43-7.